<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857804</url>
  </required_header>
  <id_info>
    <org_study_id>olivier1</org_study_id>
    <nct_id>NCT01857804</nct_id>
  </id_info>
  <brief_title>Surgical Treatment of Peri-implantitis</brief_title>
  <official_title>Surgical Treatment of Peri-implantitis With and Without Adjunctive Use of Antibiotics : a Controlled and Randomized Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this randomized controlled clinical trial is to evaluate the outcome of
      treatment of peri-implantitis with or without systemic antibiotics.

      Specific aims are to analyze (i) the effect of systemic antibiotics and local antiseptics on
      the healing process, and (ii) the risk for recurrence of disease following surgical treatment
      of peri-implantitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a randomized controlled clinical trial. 100 patients with severe
      peri-implantitis at one or more implants needing surgical treatment will be recruited. All
      individuals have to show unremarkable general health and not been using any antibiotics
      during the 6 months preceding the current examination.

      The patients will be randomly assigned to the following :

        -  test group (T) : surgical treatment with systemic antibiotics,

        -  control group (C) : surgical treatment without systemic antibiotics. A stratification
           protocol will be applied regarding distribution of smokers. Two subgroups will be formed
           among test and control subjects.

        -  saline group (T1 and C1) : the exposed implant surfaces will be cleaned 3 minutes with
           saline during the surgical treatment, and,

        -  antiseptics group (T2 and C2) : the exposed implant surfaces will be cleaned 3 minutes
           with antiseptics (chlorhexidine 0,2%) during the surgical treatment.

      A stratification protocol will be applied regarding distribution of smokers.

      Following the baseline examination, patients will randomly be assigned to the various
      treatment group. Samples from the subgingival microbiota will be obtained before surgical
      therapy.

      All patients will be enrolled in a hygiene program including professional supragingival
      implant/tooth cleaning using rubber cups and polishing paste and oral hygiene instructions.

      The following clinical parameters will be measured at baseline using a periodontal probe:
      plaque index, Bleeding on Probing, probing depth measured from the mucosal margin to the
      bottom of the probable pocket and mucosal recession measured from a fixed landmark on the
      implant to the mucosal margin.

      The measurements will be made at 4 aspects of each implant. In the test group (T) a systemic
      antibiotic regimen will be initiated at 3 days before surgery and continued for 10 days. (2 x
      750mg amoxicillin/day or 2 x 1g amoxicillin/day depending on the weight of the patient)
      Intra-oral radiographs will be taken at 2 weeks and 1 year after surgical therapy.

      The professional implant/tooth cleaning and reinforcement of oral hygiene will be performed
      at 2 weeks, 1, 2, 3, 6, and 12 months after treatment.

      Examination of clinical outcome variables will be performed at 3, 6 and 12 months after
      surgical therapy. Microbiological samples will be obtained at the same time points.
      Radiographs are taken 2 weeks post surgical and at the one year examination.

      Primary outcomes variables include: (i) clinical signs of resolution of peri-implantitis
      (pocket closure and absence of BoP), (ii) recurrence of the disease (BoP and increase in PPD)
      and (iii) further loss in marginal bone support, and (iiii) microbiological findings.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pocket closure</measure>
    <time_frame>6 months, 1 year</time_frame>
    <description>absence of probing pocket depth &gt; 5 mm and no bleeding on probing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>bone level stability</measure>
    <time_frame>1 year</time_frame>
    <description>no further peri-implant marginal bone loss in the observation period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative and qualitative change in levels of the peri-implant microflora</measure>
    <time_frame>3 months, 6 months, 1 year</time_frame>
    <description>Quantitative and qualitative change in levels of the peri-implant microflora</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Peri-Implantitis</condition>
  <arm_group>
    <arm_group_label>antibiotics and local antiseptics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with chlorhexidine gluconate 0,2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antibiotics without local antiseptics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>local antiseptics no antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>no systemic antibiotics + implant surface decontamination with chlorhexidine gluconate 0,2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no antibiotics and no local antiseptics</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>no systemic antibiotics + implant surface decontamination with saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>In the test group a systemic antibiotic regimen will be initiated at 3 days before surgery and continued for 10 days. (2 x 750mg amoxicillin/day or 2 x 1g amoxicillin/day depending on the weight of the patient)</description>
    <arm_group_label>antibiotics and local antiseptics</arm_group_label>
    <arm_group_label>antibiotics without local antiseptics</arm_group_label>
    <other_name>systemic antibiotics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine gluconate</intervention_name>
    <description>The exposed implant surfaces will be cleaned 3 minutes with antiseptics (chlorhexidine gluconate 0,2%) during the surgical treatment</description>
    <arm_group_label>antibiotics and local antiseptics</arm_group_label>
    <arm_group_label>local antiseptics no antibiotics</arm_group_label>
    <other_name>chlorhexidine gluconate 0,2%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>The exposed implant surfaces will be cleaned 3 minutes with saline during the surgical treatment</description>
    <arm_group_label>no antibiotics and no local antiseptics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  peri-implant probing pocket depth &gt; 7 mm on at least one aspect of the implant,
             together with BOP and/or suppuration,

          -  marginal bone loss &gt; 3mm as detected in radiographs.

        Exclusion Criteria:

          -  implant mobility,

          -  peri-implantitis associated bone defects not suitable for pocket elimination therapy,

          -  systemic diseases that could influence the outcome of the therapy,

          -  penicillin allergy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tord Berglundh, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Periodontology, Institute of Odontology, The sahlgrenska academy, University of Gothenburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Periodontology, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg</name>
      <address>
        <city>Gothenburg</city>
        <zip>40530</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Albouy JP, Abrahamsson I, Persson LG, Berglundh T. Implant surface characteristics influence the outcome of treatment of peri-implantitis: an experimental study in dogs. J Clin Periodontol. 2011 Jan;38(1):58-64. doi: 10.1111/j.1600-051X.2010.01631.x. Epub 2010 Nov 24.</citation>
    <PMID>21092053</PMID>
  </reference>
  <reference>
    <citation>Ericsson I, Persson LG, Berglundh T, Edlund T, Lindhe J. The effect of antimicrobial therapy on periimplantitis lesions. An experimental study in the dog. Clin Oral Implants Res. 1996 Dec;7(4):320-8.</citation>
    <PMID>9151598</PMID>
  </reference>
  <reference>
    <citation>Gualini F, Berglundh T. Immunohistochemical characteristics of inflammatory lesions at implants. J Clin Periodontol. 2003 Jan;30(1):14-8.</citation>
    <PMID>12702106</PMID>
  </reference>
  <reference>
    <citation>Leonhardt A, Dahlén G, Renvert S. Five-year clinical, microbiological, and radiological outcome following treatment of peri-implantitis in man. J Periodontol. 2003 Oct;74(10):1415-22.</citation>
    <PMID>14653386</PMID>
  </reference>
  <reference>
    <citation>Mombelli A, Feloutzis A, Brägger U, Lang NP. Treatment of peri-implantitis by local delivery of tetracycline. Clinical, microbiological and radiological results. Clin Oral Implants Res. 2001 Aug;12(4):287-94. English, French, German.</citation>
    <PMID>11488856</PMID>
  </reference>
  <reference>
    <citation>Mombelli A, Lang NP. Antimicrobial treatment of peri-implant infections. Clin Oral Implants Res. 1992 Dec;3(4):162-8.</citation>
    <PMID>1298430</PMID>
  </reference>
  <reference>
    <citation>Persson LG, Ericsson I, Berglundh T, Lindhe J. Guided bone regeneration in the treatment of periimplantitis. Clin Oral Implants Res. 1996 Dec;7(4):366-72.</citation>
    <PMID>9151604</PMID>
  </reference>
  <reference>
    <citation>Persson LG, Ericsson I, Berglundh T, Lindhe J. Osseintegration following treatment of peri-implantitis and replacement of implant components. An experimental study in the dog. J Clin Periodontol. 2001 Mar;28(3):258-63.</citation>
    <PMID>11284540</PMID>
  </reference>
  <reference>
    <citation>Persson LG, Mouhyi J, Berglundh T, Sennerby L, Lindhe J. Carbon dioxide laser and hydrogen peroxide conditioning in the treatment of periimplantitis: an experimental study in the dog. Clin Implant Dent Relat Res. 2004;6(4):230-8.</citation>
    <PMID>15841583</PMID>
  </reference>
  <reference>
    <citation>Wetzel AC, Vlassis J, Caffesse RG, Hämmerle CH, Lang NP. Attempts to obtain re-osseointegration following experimental peri-implantitis in dogs. Clin Oral Implants Res. 1999 Apr;10(2):111-9.</citation>
    <PMID>10219130</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2013</study_first_submitted>
  <study_first_submitted_qc>May 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <last_update_submitted>November 12, 2014</last_update_submitted>
  <last_update_submitted_qc>November 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peri-implantitis</keyword>
  <keyword>surgical therapy</keyword>
  <keyword>systemic antibiotics</keyword>
  <keyword>local antiseptics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peri-Implantitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Anti-Infective Agents, Local</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

